Update on Therapies to Treat Diabetic Nephropathy
ACE inhibitor or angiotensin 2 receptor blocker therapy is a standard of care for hypertension management in people with diabetes and albuminuria. Additionally, recent trials have elucidated the roles of additional therapeutic agents, including the sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and the recently approved mineralocorticoid receptor antagonist finerenone, in the treatment of chronic kidney disease in people with type 2 diabetes. This article provides an evidence-based review of therapies that may delay the progression of kidney disease in this population.

Source: https://diabetesjournals.org/clinical/article-abstract/40/3/305/144721/Protecting-the-Kidneys-Update-on-Therapies-to?redirectedFrom=fulltext